计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| L647658-1mg |
1mg |
期货 ![]() |
| |
| L647658-5mg |
5mg |
期货 ![]() |
| |
| L647658-10mg |
10mg |
期货 ![]() |
|
| 别名 | 卢马西兰 |
|---|---|
| 规格或纯度 | ≥95% |
| 英文名称 | Lumasiran |
| 生化机理 | Lumasiran(ALN-G01)是一种 siRNA 产品,通过靶向乙醇酸氧化酶减少肝脏草酸盐的产生。通过沉默编码乙醇酸氧化酶的基因,Lumasiran 可消耗乙醇酸氧化酶,从而抑制草酸盐的合成,而草酸盐是肝脏产生草酸盐的主要来源。 |
| 储存温度 | -20°C储存,充氩,干燥 |
| 运输条件 | 超低温冰袋运输 |
| 产品介绍 |
Lumasiran (ALN-G01), a siRNA product, reduces hepatic oxalate production by targeting glycolate oxidase. By silencing the gene encoding glycolate oxidase, Lumasiran depletes glycolate oxidase and thereby inhibits the synthesis of oxalate, which is the toxic metabolite that is directly associated with the clinical manifestations of Primary hyperoxaluria type 1 (PH1). In Vitro Lumasiran reduced urinary oxalate excretion, the cause of progressive kidney failure in PH1. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo Lumasiran is a subcutaneously administered, liver-directed RNA interference (RNAi) therapeutic agent. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid |
| 纯度 | ≥95% |
| Smiles | [Lumasiran] |
|---|---|
| 分子量 | 16339.00 (AS: 7631.0 +SS: 8708.0) |
| 溶解性 | H2O : 100 mg/mL (Need ultrasonic) |
|---|